TWST
Company Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M | 25.43M | 10.77M | 2.27M |
| Net Income | (77.67M) | (208.73M) | (204.62M) | (217.86M) | (152.10M) | (139.93M) | (107.67M) | (71.24M) | (59.31M) | (44.09M) |
| EPS | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Free Cash Flow | (75.63M) | (69.17M) | (170.25M) | (226.24M) | (139.31M) | (152.12M) | (102.69M) | (69.85M) | (57.90M) | (44.82M) |
| FCF / Share | -1.26 | -1.19 | -2.99 | -4.20 | -2.89 | -3.88 | -3.74 | -2.63 | -3.08 | -2.39 |
| Operating CF | (47.63M) | (64.09M) | (142.47M) | (124.39M) | (112.24M) | (142.25M) | (87.94M) | (66.16M) | (51.30M) | (38.59M) |
| Total Assets | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M | 115.79M | 85.66M | 76.46M |
| Total Debt | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M | 35.98M | 7.73M | 9.72M | 9.15M | 11.18M |
| Cash & Equiv | 183.05M | 226.32M | 286.47M | 378.69M | 465.83M | 93.67M | 46.73M | 80.76M | 31.23M | 28.60M |
| Book Value | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M | 336.26M | 152.08M | (201.42M) | (133.36M) | (76.61M) |
| Return on Equity | -0.16 | -0.44 | -0.33 | -0.28 | -0.26 | -0.42 | -0.71 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 110.72M | 103.70M | 99.01M | 96.06M | 92.79M | 88.71M | 84.71M | 81.46M | 75.30M | 71.50M | 66.95M | 63.74M |
| Net Income | (44.02M) | (30.51M) | (27.14M) | 20.39M | (39.33M) | (31.59M) | (34.66M) | (85.57M) | (45.49M) | (43.01M) | (46.24M) | (57.40M) |
| EPS | -0.71 | -0.50 | -0.45 | 0.34 | -0.66 | -0.53 | -0.60 | -1.47 | -0.79 | -0.75 | -0.81 | -1.01 |
| Free Cash Flow | (25.55M) | (34.79M) | (24.24M) | (10.56M) | (17.13M) | (23.70M) | (17.32M) | (7.34M) | (20.03M) | (24.48M) | (23.10M) | (27.92M) |
| FCF / Share | -0.41 | -0.57 | -0.40 | -0.18 | -0.29 | -0.40 | -0.30 | -0.13 | -0.35 | -0.43 | -0.40 | -0.49 |
| Operating CF | (17.56M) | (24.81M) | (11.81M) | (1.40M) | (12.99M) | (21.43M) | (15.32M) | (6.38M) | (19.42M) | (22.97M) | (20.70M) | (23.41M) |
| Total Assets | 676.21M | 638.09M | 641.86M | 643.61M | 595.62M | 608.58M | 614.32M | 638.12M | 702.85M | 732.82M | 776.40M | 810.33M |
| Total Debt | 95.84M | 183.86M | 137.32M | 78.15M | 80.30M | 82.62M | 85.03M | 87.18M | 89.42M | 91.88M | 94.07M | 93.03M |
| Cash & Equiv | 122.67M | 148.59M | 183.05M | 201.37M | 210.44M | 221.40M | 226.32M | 239.14M | 243.35M | 266.27M | 286.47M | 307.46M |
| Book Value | 455.09M | 456.10M | 472.96M | 478.20M | 440.11M | 455.94M | 472.69M | 491.14M | 560.13M | 590.04M | 623.43M | 657.55M |
| Return on Equity | -0.10 | -0.07 | -0.06 | 0.04 | -0.09 | -0.07 | -0.07 | -0.17 | -0.08 | -0.07 | -0.07 | -0.09 |
